Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil and Vitamin E for Cognitive Dysfunction Prevention in SCLC After PCI
NCT00006349Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2001
- Primary completion
- Jan 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cognitive dysfunction and acute radiation syndrome (ARS) comparing donepezil + vitamin E with placebo (2 arms). Primary endpoint: Interval between completion of cancer treatment and onset of cognitive decline at 6 months. Started Feb 2001; status: completed.
02
Drugs
donepezilvitamin e
03
Conditions
cognitive dysfunctionacute radiation syndrome (ARS)
Beyond the preview
Go deeper on NCT00006349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006349.